FOCUS ON PERIPHERAL ARTERY DISEASE (PAD)

In Europe and North America, an estimated 27 million individuals are affected with peripheral artery disease (PAD), which is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg) reducing blood flow. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

CBSET is committed to the development of novel experimental and computational models for defining the barrier effects of tissue components on drugs of interest and evaluating novel endovascular therapies. CBSET’s scientists have published a range of data and analyses on PAD treatments and related therapies.

RamiCRT2019Innovation3At CRT19, CBSET’s Director of Research and Innovation, Rami Tzafriri, PhD, was interviewed by Michael Mooney, MD, of Minneapolis Heart Institute, Abbott Northwestern hospital about CBSET’s PAD preclinical study: Enhanced Plaque Modification of Cadaveric Human Calcified Peripheral Arteries Treated with a Vessel Preparation System. In this interview, Rami discusses CBSET’s human cadaver model assessment of a vessel preparation system and the attributes of this particular technology that suggest it might be conducive to enhancing drug absorption.

A recent CBSET paper, Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics, published in the Journal of Controlled Release, provides critical insights into the determinants of the arterial retention of paclitaxel and specificity of effect.

Recent scientific papers/presentations related to novel PAD therapies:

Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. Abraham R.Tzafriri, Sahil A.Parikh, Elazer R.Edelman. Journal of Controlled Release. Volume 310, 28 September 2019, Pages 94-102.

Enhanced Plaque Modification of Cadaveric Human Calcified Peripheral Arteries Treated with a Vessel Preparation System. Video interview at CRT19. CBSET’s Director of Research and Innovation, Rami Tzafriri, PhD, discusses CBSET’s human cadaver model assessment of a vessel preparation system and the attributes of this particular technology that suggest it might be conducive to enhancing drug absorption.

Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis. Abraham R. Tzafriri, Fernando Garcia-Polite, Brett Zani, James Stanley, Benny Muraj, Jennifer Knutson, Robert Kohler, Peter Markham, Alexander Nikanorov, Elazer R. Edelman,  Journal of Controlled Release, Volume 264, 28 October 2017, Pages 203-210.

Mechanisms Underlying Drug Delivery to Peripheral Arteries. Li J, Tzafriri R, Patel SM, Parikh SA. Interventional Cardiology Clinics. 2017 Apr;6(2):197-216. doi: 10.1016/j.iccl.2016.12.004.

Two Blades-Up Runs Using the JetStream Navitus Atherectomy Device Achieve Optimal Tissue Debulking of Nonocclusive In-Stent Restenosis: Observations From a Porcine Stent/Balloon Injury Model. Shammas NW, Aasen N, Bailey L, Budrewicz J, Farago T, Jarvis G. Journal of Endovascular Therapy. 2015 Aug;22(4):518-24.

Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy. Vijaya B. Kolachalama, Stephen D. Pacetti, Joseph W. Franses, John J. Stankus, Hugh Q. Zhao, Tarek Shazly, Alexander Nikanorov, Lewis B. Schwartz, Abraham R. Tzafriri, Elazer R. Edelman. Circulation. 2013;127:2047-2055.

Correlative evaluation of variable pressure-scanning electron microscopy to histology methods for vascular tissues. P. Seifert, K. Regan, B.G. Zani, G. Wong, and J. Stanley. Journal of Histotechnology, 2013 March; 36 (1): 25-29.

Related CBSET Brochures:

CBSET GLP Preclinical Services

Cardiovascular Research

GLP Histopathology and Morphometry

Computational Modeling of Local Drug Delivery

Scanning Electron Microscopy